Chemists Assess Opportunities In Their Changing Profession

Attending some scientific conferences can be as frustrating for the career-driven researcher as a stroll through a bookstore is for the book-starved browser. With offerings so vast, one simply may not have the time or the energy to satisfy the intellectual appetite. In the spring of 1990, the advisory committee to the NSF chemistry division decided to conduct its annual meeting a little differently. Instead of devoting one hour to one topic before moving on to another, committee members deci

Written byRobin Eisner
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

In the spring of 1990, the advisory committee to the NSF chemistry division decided to conduct its annual meeting a little differently. Instead of devoting one hour to one topic before moving on to another, committee members decided to hold the meeting like a retreat. Says NSF chemistry division director Kenneth Hancock: "We decided to sit back and literally ask where the intellectual frontiers in chemistry are and where we think our science is and ought to be going in the next few years." Out of that "retreat" came a set of priorities that are used by NSF management when it makes its case for research funding appropriations. "It is a very interactive process that includes [recommendations by] this division, studies by the National Research Council, and the chemical community at large," Hancock says. To communicate the priorities he and his associates identified, Hancock uses the letters of the word ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies